A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2013
At a glance
- Drugs Efaproxiral (Primary) ; Carmustine
- Indications Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 20 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 31 Oct 2006 Status change
- 17 Aug 2005 New trial record.